MX370808B - Compuesto novedoso sustituido con quinolina. - Google Patents
Compuesto novedoso sustituido con quinolina.Info
- Publication number
- MX370808B MX370808B MX2016002125A MX2016002125A MX370808B MX 370808 B MX370808 B MX 370808B MX 2016002125 A MX2016002125 A MX 2016002125A MX 2016002125 A MX2016002125 A MX 2016002125A MX 370808 B MX370808 B MX 370808B
- Authority
- MX
- Mexico
- Prior art keywords
- substituted compound
- novel quinoline
- egfr
- present
- inhibiting activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Un objeto que puede lograrse con la presente invención es proporcionar un compuesto novedoso que tiene efectos inhibidores de EGFR y efectos inhibidores del crecimiento celular, así como un medicamento útil para la prevención y/o tratamiento del cáncer basado en los efectos inhibidores de EGFR; la presente invención proporciona un compuesto representado por la fórmula (I) a continuación, o una sal del mismo. (ver Fórmula).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013172746 | 2013-08-22 | ||
PCT/JP2014/071951 WO2015025936A1 (ja) | 2013-08-22 | 2014-08-22 | 新規キノリン置換化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016002125A MX2016002125A (es) | 2016-06-28 |
MX370808B true MX370808B (es) | 2020-01-07 |
Family
ID=52483707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016002125A MX370808B (es) | 2013-08-22 | 2014-08-22 | Compuesto novedoso sustituido con quinolina. |
Country Status (22)
Country | Link |
---|---|
US (2) | US9650386B2 (es) |
EP (1) | EP3037424B1 (es) |
JP (1) | JP6161705B2 (es) |
KR (1) | KR101906688B1 (es) |
CN (1) | CN105683195B (es) |
AU (1) | AU2014309788B2 (es) |
BR (1) | BR112016003247B1 (es) |
CA (1) | CA2922077C (es) |
DK (1) | DK3037424T3 (es) |
ES (1) | ES2656712T3 (es) |
HK (1) | HK1222393A1 (es) |
HU (1) | HUE034807T2 (es) |
MX (1) | MX370808B (es) |
MY (1) | MY182891A (es) |
NO (1) | NO3037424T3 (es) |
PH (1) | PH12016500225B1 (es) |
PL (1) | PL3037424T3 (es) |
PT (1) | PT3037424T (es) |
RU (1) | RU2689158C2 (es) |
SG (1) | SG11201600759XA (es) |
TW (1) | TWI603971B (es) |
WO (1) | WO2015025936A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6161705B2 (ja) * | 2013-08-22 | 2017-07-12 | 大鵬薬品工業株式会社 | 新規キノリン置換化合物 |
JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
MX2019005834A (es) * | 2016-11-17 | 2019-10-14 | Univ Texas | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2. |
CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
FR3068971B1 (fr) * | 2017-07-12 | 2019-08-30 | Protneteomix | Acides 5-{4-allyl-5-[2-(4-alcoxyphenyl)quinolein-4-yl]-4h-1,2,4-triazole-3-ylsulphanylmethyl}furan-2-carboxyliques dans le traitement du cancer |
CA3074418C (en) | 2017-09-01 | 2024-04-23 | Taiho Pharmaceutical Co., Ltd. | Exon 18 and/or exon 21 mutant egfr selective inhibitor |
AU2019417691A1 (en) * | 2018-12-28 | 2021-07-22 | Taiho Pharmaceutical Co., Ltd. | L718 and/or L792 mutant treatment-resistant EGFR inhibitor |
BR112021018704B1 (pt) | 2019-03-19 | 2023-01-10 | Voronoi Inc. | Derivado de heteroarila, método para produção do mesmo, e composição farmacêutica compreendendo a mesma como componente eficaz |
WO2021057796A1 (zh) * | 2019-09-29 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的稠合三环衍生物及其组合物及用途 |
WO2021127456A1 (en) | 2019-12-19 | 2021-06-24 | Rain Therapeutics Inc. | Methods of inhibiting epidermal growth factor receptor proteins |
CN113861195B (zh) * | 2020-06-30 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种多稠环egfr抑制剂及其制备方法和应用 |
WO2022007841A1 (zh) * | 2020-07-09 | 2022-01-13 | 上海和誉生物医药科技有限公司 | 一种egfr抑制剂、其制备方法和在药学上的应用 |
WO2022055895A1 (en) * | 2020-09-08 | 2022-03-17 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
JP2024523861A (ja) | 2021-06-15 | 2024-07-02 | ジェネンテック, インコーポレイテッド | がんを処置するための併用療法におけるegfr阻害剤およびperk活性化剤、ならびにこれらの使用 |
CN115707704A (zh) * | 2021-08-20 | 2023-02-21 | 中山医诺维申新药研发有限公司 | 氘代稠合三环类化合物及其组合物和用途 |
WO2024121805A1 (en) * | 2022-12-08 | 2024-06-13 | Assia Chemical Industries Ltd. | Solid state forms of zipalertinib and process for preparation thereof |
CN115785107A (zh) * | 2022-12-15 | 2023-03-14 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
CA2601766A1 (en) | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
CA2767556C (en) | 2009-07-10 | 2017-11-28 | Taiho Pharmaceutical Co., Ltd. | Azabicyclo compound and salt thereof |
US7718662B1 (en) * | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
CA2824013A1 (en) | 2011-01-07 | 2012-07-12 | Taiho Pharmaceutical Co., Ltd. | Novel bicyclic compound or salt thereof |
JP5878178B2 (ja) | 2011-09-30 | 2016-03-08 | 大鵬薬品工業株式会社 | 1,2,4−トリアジン−6−カルボキサミド誘導体 |
TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
WO2013118817A1 (ja) | 2012-02-07 | 2013-08-15 | 大鵬薬品工業株式会社 | キノリルピロロピリミジン化合物又はその塩 |
US8889666B2 (en) | 2012-02-23 | 2014-11-18 | Taiho Pharmaceutical Co., Ltd. | Quinolyl pyrrolo pyrimidyl condensed-ring compound and salt thereof |
KR20150119401A (ko) * | 2013-02-22 | 2015-10-23 | 다이호야쿠힌고교 가부시키가이샤 | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 |
JP6161705B2 (ja) * | 2013-08-22 | 2017-07-12 | 大鵬薬品工業株式会社 | 新規キノリン置換化合物 |
-
2014
- 2014-08-22 JP JP2015532903A patent/JP6161705B2/ja active Active
- 2014-08-22 AU AU2014309788A patent/AU2014309788B2/en active Active
- 2014-08-22 PL PL14837210T patent/PL3037424T3/pl unknown
- 2014-08-22 US US14/911,093 patent/US9650386B2/en active Active
- 2014-08-22 WO PCT/JP2014/071951 patent/WO2015025936A1/ja active Application Filing
- 2014-08-22 EP EP14837210.5A patent/EP3037424B1/en active Active
- 2014-08-22 HU HUE14837210A patent/HUE034807T2/en unknown
- 2014-08-22 CA CA2922077A patent/CA2922077C/en active Active
- 2014-08-22 BR BR112016003247-0A patent/BR112016003247B1/pt active IP Right Grant
- 2014-08-22 RU RU2016110096A patent/RU2689158C2/ru active
- 2014-08-22 MY MYPI2016700465A patent/MY182891A/en unknown
- 2014-08-22 SG SG11201600759XA patent/SG11201600759XA/en unknown
- 2014-08-22 PT PT148372105T patent/PT3037424T/pt unknown
- 2014-08-22 TW TW103129036A patent/TWI603971B/zh active
- 2014-08-22 ES ES14837210.5T patent/ES2656712T3/es active Active
- 2014-08-22 NO NO14837210A patent/NO3037424T3/no unknown
- 2014-08-22 MX MX2016002125A patent/MX370808B/es active IP Right Grant
- 2014-08-22 DK DK14837210.5T patent/DK3037424T3/en active
- 2014-08-22 KR KR1020167007071A patent/KR101906688B1/ko active IP Right Grant
- 2014-08-22 CN CN201480058192.XA patent/CN105683195B/zh active Active
-
2016
- 2016-02-02 PH PH12016500225A patent/PH12016500225B1/en unknown
- 2016-09-06 HK HK16110581.6A patent/HK1222393A1/zh unknown
- 2016-12-19 US US15/382,883 patent/US9758526B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016500225A1 (en) | Novel quinoline-substituted compound | |
PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
MA40076A (fr) | Inhibiteurs de syk | |
TN2015000516A1 (en) | Chemical compounds | |
IN2015DN01156A (es) | ||
MD4659B1 (ro) | Polimorf al inhibitorilor SYK | |
UA110354C2 (uk) | Противірусні сполуки | |
EA201590661A1 (ru) | Азахиназолиновые ингибиторы атипичной протеинкиназы c | |
WO2014031928A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
IN2014MN02459A (es) | ||
MX2012012530A (es) | Derivados de n1-sulfonil-5-fluorpirimidinona. | |
GEP20196942B (en) | Heterocyclic compounds and their use as retinoidrelated orphan receptor (ror) gamma-t inhibitors | |
EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
WO2014031933A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
PH12016500003A1 (en) | Compounds and compositions as inhibitors of mek | |
IN2015DN01151A (es) | ||
WO2014031936A3 (en) | Heterocyclic modulators of hif activity for treatment of disease | |
PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
MX349548B (es) | Compuestos de tienopirimidina. | |
MX2015013936A (es) | Compuestos de pirimidina condensada sustituida. | |
MX2016004967A (es) | Tratamiento para cancer pancreatico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |